Recent appointments at Immune Response Biopharma

At one time David Buswell said the the former executives at Immune Response Inc. aka Orchestra Therapeutic caused the companies failure and not the research. I find it interesting that now many of those some people are members of the new Immune Response BioPharma. My belief is that these are the people behind Immune Response Biopharma and that they deliberately caused the company to go bankrupt in order to take the research and start a new company called Immune Response BioPharma so they could dump all the previous investors, start a new company, and reap all the profits for themselves. I suspect it is only a matter of time till we hear that Kevin Kimberlin and Spencer Trask are now involved in the new Immune Response BioPharma.

Boards and new Advisors at Immune Response Biophama

It appears that many of the people who were previously involved in Immune Response Corporation and Orchestra Therapeutics are now joining Immune Response BioPharma. This proves my belief that the original companies research was stolen and the company itself manipulated into backruptcy so that a new company could be formed and the previous investors dumped and cheated out of their investments. Basically what has happened is that Kevin Kimberlin and Spencer Trask and the rest of the people who were at Immune Response Corp. manipulated the company so that they could change the name to Orchestra Theraputics and then purchase all the intellectural property rights to the research. They then manipulated the company into bankruptcy so they could dump all the original investors. Now they are starting a new company claming that have all the rights to the research funded by investors for over twenty years through Immune Response and Orchestra Thera. All the original crooks that were running Orchestra at the end will end up back in leadership roles with this new Immune Response Biopharma where they will cash in on the research while cheating the original investors out of everything. Typical Wall Street maneuver to make make as much profit as you can for yourself.

Open letter to Editors on Immune Response BioPharma

I have begun sending out letters to various publications seeking an investigative report into the actions of Immune Response BioPharma and the original Immune Response Inc/Orchestra Therapeutic.

Editor 

Dear Sir or Madam:

I am writing to suggest a story that your publication might find interesting enough to pursue.  I am a long time investor in a company called Orchestra Therapeutic Corporations Inc. The company began under the name Immune Response Inc.(IMNR) in the 1980s under Jonas Salk and Kevin Kimberlin with Spencer Trask to find a cure for aids, rheumatoid arthritis, psoriasis, and other diseases. Orchestra Therapeutic now trades under the symbol OCHTQ after going through a bankruptcy.  

Recently another research company called Immune Response BioPharma was created under the leadership of David Buswell. This company now claims to own all the intellectual property and research rights of  Immune Response/Orchestra Therapeutic saying that the research was legally abandoned. When I contacted Eric Swanson Communications Officer at Immune Response Biophrma he replied with the following:
"Per your note to Mr. Buswell, it's my understanding you have issues relating to his medical and business efforts. While I'm not a brankruptcy expert, I believe the science he has embraced was abandoned by the parties you mentioned in your email. It seems to me he's trying to make good on something that was left to the trash collectors." and that what they found was “in the trash can.” Recently David Buswell the company’s CEO has said in released statements, “REMUNE is a winner hands down and see the vaccine as the gold standard of treatment, eventually 90% market share.” 

It seems a little hard to believe that scientific research involving clinical trials involving patients could be retrieved from a trash can and that this same research could then turn out to be a gold mine. Investors holding shares in Orchestra/Immune Response like myself are concerned that the original Immune Response’s operations were handled in such a way as to force a bankruptcy so that the research could then be transferred to another company where it could then be reissued as an IPO thus abandoning the original investors. I have written numerous letters and E-mails to Kevin Kimberlin and Spencer Trask asking if there was any connection between them and the new Immune Response BioPharma, but they have refused to reply as has David Buswell.

In fact the only response I have been able to obtain from David Buswell was in the form of threats such as the following:

“I would ask you to respect the rule of law and cease and desist from contacting, harassing, interference of business, fraud, manipulation, slander, defamation, illegal activities, written or oral communication threathening, harming, cyber attacks, physical or oral or via mail any blackmail or greenmail activities or otherwise prohibited illegal activities against Immune Response BioPharma or its employees, founders or members in any shape form or fashion will be deemed as hostile acts and reported to the proper authorities. Immune Respone BioPharma is a peaceful company only seeking to save lives and has its own pipeline of life saving drugs and will act responsibly by developing those therapeutic treatments in the of mankind. Should you continue with your course of actions it will become a criminal matter which the proper authorities will be notified, at this time Immune Response BioPharma will not pursue any legal actions but cautions you to refrain from further activities that would otherwise violate the rule of law. Mr. Reese make no mistake you will be held accountable should you continue to harrass, impede, threathen, blackmail, interfere with our business and notify the Department of Justice and the FBI should you send more harrassing emails. Please Cease & Desist as of 2/24/2011 your activities and contact with Immune Response BioPharma, should you violate this order appropriate legal action will be taken. Immune Response BioPharma will use any and all legal avenues civil and criminal to halt any violations of this order.

Sincerely, Immune Response BioPharma Legal Department”

It seems the new Immune Response has not only tried to take over the research, but also the name Immune Response and has started a new unit called,(you guessed it) Orchestra Therapeutics. It claims Orchestra Therapeutics will focus on the development of new antibiotics and manufacturing of Generic antibiotics.

Obviously, for the legal rights of the original stockholders to have been abandoned legally there could be no involvement in Immune Response BioPharma by either Mr. Kimberlin or Spencer Trask as that would simply mean that they helped finance and start a new company under a new name and simply transferred the research rights in order to abandon the previous companies investors and make more profit for themselves.

I would like to encourage your publication to investigate the new Immune Response BioPharma and how this company is conducting its business in light of the information you now have. I could make for a very interesting story in light of the connection with Jonas Salk and the renewed attention that Aids research is now receiving.

Immune Response and Orchestra stock manipulation

The price of Orchestra Therapeutics stays at 0.0035. Twice in the past few weeks including last week I purchased shares in of the stock at the market price which was .01 cents a share bringing the last purchase price up to .01 cents on the financial board. Both times there was an immediate trade of over 300 shares at 0.0035 bringing the price of the stock back down. Could it be that someone is purposely trying to manipulate the price of the stock to keep it below .01 cents a share. I mean why would someone offer to sell at 0.0035 when the last trade was higher and why would it always be the same price and the same amount of stock being exchanged. I wounder if someone is not deliberately trying to keep the price down at 0.0035 Does anyone have a guess as to what reason they might have?            

Orchestra Therapeutics and Immune Response BioPharma

The so called new Immune Response BioPharma company that claims to now own the research from Immune Response/Orchestra Therapeutics has now annouced that it has started a new unit called,(you guessed it) Orchestra Therapeutics. It claims Orchestra Therapeutics will focus on the development of new antibiotics and manufacturing of Generic antibiotics. Can you believe that? First they claim to be a whole new company and call themselves Immune Response BioPharma. Only this so called new company's claim to fame is the fact that they say they now own the rights to all the research of another company by the name of (you guessed it) Immune Response Corporation. Now they claim to be starting a new unit by the name of (you guessed it again) Orchestra Therapeutics which just happens to be the name that Immune Response Corporation changed to and still trades under as OCHTQ.PK. Apparently the primary goal of David Buswell and his accomplices is too not only steal the research financed by the investors in IMNR/OCHTQ.PK, but also to steal the names as well. I can't figure out if they know they are running a scam and aren't worried about the long term outcome of their actions or if they think that investors will be so blind as to not see that these companies are all one and the same. The only thing different is that insiders have tried to manipulate the original companies so that they could cheat the original investors, steal the research, and make all the profits.

Immune Response BioPharma Stock

I purchased another 3000 shares of Orchestra Theraputic (OCHTQ.PK) today. It is important that stock holders in Immune Response/Orchestra Therap keep the stock active to help protect our rights and to make sure it stays active on the trading boards.

Immune Response Biopharma and Rheumatoid Arthritis

I have a sister and a best friend who suffer from Rheumatoid arthritis. It is the reason I invested in the company to begin with. I wonder if David Buswell and Immune Response Biopharma "found" that research abandoned somewhere also and now say it is theirs.

"The Immune Response Corporation (Nasdaq: IMNR) announced today that it has received United States Patent Number 6,207,645 expanding coverage relating to its immune-based therapy for rheumatoid arthritis, RAVAX(TM). The recently issued patent has specific claims covering immunization utilizing DNA vaccines that are designed to synthesize the T cell receptor (TCR) Vbeta specific peptides in situ, in contrast to immunizing directly with the TCR peptides themselves. The patent also includes specific claims for DNA vaccines encoding key "superantigen" protein sequences from the Vbeta 3, Vbeta 14 and Vbeta 17 regions of the TCR present on the surface of these pathogenic T cells thought to be associated with rheumatoid arthritis. The Company believes that vaccination with RAVAX may inhibit the disease-associated T cells that cause rheumatoid arthritis, and prevent further damage in patients suffering from the disease. "This recent issuance is a key patent in that it extends previous coverage related to the delivery and composition of RAVAX to now include DNA vaccines in addition to peptide vaccines," said Richard Bartholomew, Ph.D., Executive Director of Research Operations for The Immune Response Corporation. "DNA vaccination is proving to be an effective method of inducing immunity against a number of human diseases. The issuance of this patent to include DNA vaccination for our peptide vaccine program serves to further strengthen our intellectual property position in the field of T cell receptor vaccine research." The Company previously announced that it was issued U.S. patent number 6,090,387 for vaccinating with T cell receptor peptides on August 9, 2000. Several autoimmune disorders, including rheumatoid arthritis, psoriasis and multiple sclerosis, are thought to result in part from the proliferation of "autoreactive pathogenic T cells," immune cells that incorrectly identify the body's own cells as foreign and destroy them. The Immune Response Corporation has completed two Phase II clinical trials in rheumatoid arthritis using their proprietary immune-based therapy based on TCR peptide vaccines. In a phase IIb trial of 340 rheumatoid arthritis patients, RAVAX demonstrated safety and tolerability, and suggested a statistically significant treatment effect at one time point after the third injection using criteria established by the American College of Rheumatology (ACR 20). The ACR 20 criteria require an improvement in tender and swollen joint counts of at least 20% from baseline, along with improvement in three of five other disease-related criteria. To date, no clinical studies have been initiated utilizing the DNA vaccination approach."